跳至主要内容
临床试验/CTRI/2019/05/018990
CTRI/2019/05/018990已完成Unknown

A comparative study of the safety, efficacy, quality of life outcome and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in patients of new onset focal seizures

Institutional sponsored1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年8月5日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Minimal adverse drug reactions and seizure freedom

研究概览

简要总结

The study is being done to compare the safety, efficacy, quality of life outcome and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in adult patients of new onset focal seizures.

The study will be a randomized, prospective, open label, comparative interventional study.

The study will be conducted in the Department of Neurology and the Department of Pharmacology at Dr. R.P.G.M.C, Kangra at Tanda which is a 500 bedded multispeciality tertiary health care centre situated in Himachal Pradesh in India.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • The study will include all the newly diagnosed consenting adult patients of focal seizures without any other co-morbidities.

排除标准

  • Patients not willing to give written informed consent.
  • Pregnant females.
  • Patients already on treatment with study drugs.
  • Patients of seizures others than focal seizures.
  • Patients of head trauma within past one month.
  • Patients with known contraindication or refractoriness to study drugs.

结局指标

主要结局

Minimal adverse drug reactions and seizure freedom

时间窗: At 1 month, 3 months and 6 months

次要结局

  • Quality of life outcome(Before initiating treatment and at 6 months)
  • Pharmacoeconomics(At 6 months)

研究者

发起方
Institutional sponsored
申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验